23 completed, 7 unknown, 6 recruiting, 5 withdrawn. 17 Not applicable, 7 Phase 2, 5 Phase 3, 4 Phase 4, 1 Early Phase 1.
Follow Ossification, Heterotopic: new trials by email Literature Review of Ossification, Heterotopic trials Research Report on Ossification, Heterotopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) garetosmab - Fibrodysplasia Ossificans Progressiva, FOP | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 18 | 2027-02-02 | 2026-10-20 |
| A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton. Andecaliximab - Heterotopic Ossification (HO) | Phase 1 / Phase 2 | Recruiting | Ashibio Inc | 10 | 2025-05-14 | 2025-06-17 |
| IL1 Inhibition in FOP Anti-IL1 Therapy - Fibrodysplasia Ossificans Progressiva (FOP) | Recruiting | University of California, San Francisco | 11 | 2025-04-01 | 2026-08-06 | |
| A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) Andecaliximab, Placebo - Fibrodysplasia Ossificans Progressiva | Phase 2 / Phase 3 | Active not recruiting | Ashibio Inc | 92 | 2024-10-25 | 2025-10-14 |
| Edge Computing Platform for Spine Health Risk Management Based on IoT Technology Wearable Device - Cervical Disc Herniation, Cervical Spinal Stenosis | Not applicable | Completed | Xuanwu Hospital, Beijing | 40 | 2023-10-20 | 2025-07-11 |
| A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP) Non-Interventional - Fibrodysplasia Ossificans Progressiva (FOP) | Completed | Regeneron Pharmaceuticals | 131 | 2023-06-29 | 2025-07-03 | |
| Continuous Passive Motion Versus Heterotopic Ossification Continuous Passive Motion (CPM), Conventional physiotherapy (PT), Zoledronic Acid Injection - Traumatic Brain Injury, Spinal Cord Injuries | Not applicable | Recruiting | University of Ioannina | 20 | 2023-05-12 | 2024-12-06 |
| Prospective Investigation of Intra-Articular Tranexamic Acid Use in Elective Hip Arthroplasty Intra-articular Tranexamic acid application - Blood Loss, Hemoglobin Change | Active not recruiting | St. Anne's University Hospital Brno, Czech Republic | 1000 | 2023-01-01 | 2026-09-17 | |
| A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) Garetosmab, Placebo - Fibrodysplasia Ossificans Progressiva | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 63 | 2022-11-21 | 2026-07-17 |
| Celebrex and HO Study Celecoxib - Heterotopic Ossification | Unknown | McGill University Health Centre/Research Institute of the McGill University Health Centre | 200 | 2022-08-02 | 2022-12-15 | |
| Fracture and Neurological Injury Elbow surgery for fracture - Elbow Fracture, Neurologic Deficits | Withdrawn | Université de Montréal | 2022-07-01 | 2023-12-11 | ||
| Defining the Pathophysiology of Heterotopic Ossification: A Prospective Study Heterotopic Ossification | Withdrawn | Vanderbilt University Medical Center | 2022-06-01 | 2022-03-09 | ||
| To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva INCB000928, Placebo - Fibrodysplasia Ossificans Progressiva (FOP) | Phase 2 | Recruiting | Incyte Corporation | 98 | 2022-05-05 | 2026-10-22 |
| Early Ultrasound Screening of Heterotopic Ossification After Severe Neurological Trauma Ultrasound, CT scan, Clinical examination - Heterotopic Ossification | Not applicable | Unknown | Assistance Publique - Hôpitaux de Paris | 80 | 2022-03-01 | 2023-03-17 |
| Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) garetosmab - Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO) | Phase 3 | Withdrawn | Regeneron Pharmaceuticals | 2021-10-13 | 2021-11-01 | |
| Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament ACAF, Laminoplasty - Ossification of Posterior Longitudinal Ligament, Cervical Spondylosis With Myelopathy | Not applicable | Active not recruiting | Shanghai Changzheng Hospital | 167 | 2021-08-17 | 2026-05-13 |
| Comparison of IONM Between Remimazolam and Propofol Arm I (Propofol), Arm II (Remimazolam) - Ossification Posterior Longitudinal Ligament, Cervical Spondylotic Myelopathy | Not applicable | Completed | Gangnam Severance Hospital | 66 | 2021-07-20 | 2023-10-18 |
| Heterotopic Ossification Prophylaxis External Beam Radiation (XRT), Debridement - Acetabular Fracture, Heterotopic Ossification | Not applicable | Completed | University of Maryland, Baltimore | 117 | 2021-05-09 | 2024-12-16 |
| Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study STS - Systemic Sclerosis, Dermatomyositis | Phase 2 | Recruiting | University Hospital, Limoges | 40 | 2020-01-06 | 2026-09-15 |
| Balance in Patients With Ectopic Bone Tissue After Total Hip Replacement Biomechanical analysis of risk fall - Hip Osteoarthritis, Heterotopic Ossification | Completed | Medical University of Warsaw | 88 | 2020-01-01 | 2022-02-01 |
Showing 20 of 49. Sign in to see all of them.
Myositis Ossificans (12) · Ossification of Posterior Longitudinal Ligament (11) · Brain Injuries, Traumatic (2) · Elbow Fractures (2) · Hallux Valgus (2) · Intervertebral Disc Degeneration (2) · Mucopolysaccharidosis IV (2) · Osteoarthritis, Hip (2) · Spinal Cord Injuries (2) · Arthritis, Rheumatoid (1) · Bone Diseases, Infectious (1) · Dermatomyositis (1) · Femoracetabular Impingement (1) · Femoral Neck Fractures (1)
Pathologic Processes (49) · Pathological Conditions, Signs and Symptoms (49) · Musculoskeletal Diseases (28) · Bone Diseases (14) · Muscular Diseases (12) · Myositis (12) · Spinal Diseases (12) · Wounds and Injuries (7) · Nervous System Diseases (6) · Central Nervous System Diseases (4) · Connective Tissue Diseases (4) · Fractures, Bone (4) · Skin and Connective Tissue Diseases (4) · Arm Injuries (3)
Palovarotene (3) · Celecoxib (2) · Gene Fusion (2) · Laminoplasty (2) · Naproxen (2) · Radiation (2) · andecaliximab (2) · Debridement (1) · Diclofenac (1) · Etoricoxib (1) · Hemiarthroplasty (1) · High-Energy Shock Waves (1) · Ibuprofen (1) · Interleukin 1 Receptor Antagonist Protein (1) · Laminectomy (1)
Clementia Pharmaceuticals Inc. (5) · Regeneron Pharmaceuticals (4) · Shanghai Changzheng Hospital (3) · Ashibio Inc (2) · Peking University Third Hospital (2) · Seoul National University Hospital (2) · University Hospital, Limoges (2) · Aesculap AG (1) · Assaf-Harofeh Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Gangnam Severance Hospital (1) · Incyte Corporation (1) · Massachusetts General Hospital (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Medical University of Warsaw (1)
United States (18) · China (10) · France (10) · United Kingdom (7) · Australia (5) · Italy (5) · South Korea (5) · Argentina (4) · Germany (4) · Brazil (3) · Canada (3) · Japan (3) · Netherlands (3) · Spain (3) · Chile (2)
Adam Hart, MD (1) · Amanda McBride, MD (1) · Andrew Park, MD (1) · Artur Stolarczyk, PhD, MD (1) · Christian Meier, MD (1) · Chun Kee Chung, MD, PhD (1) · Dan Han, Master (1) · David Ring, MD PhD (1) · Dominique Rouleau, MD (1) · Edward Hsiao, MD, PhD (1) · Feifei Zhou, M.D. (1) · Hirotaka Chikuda, MD, PhD (1) · Jean-Edouard Loret, MD (1)
PMID 36526263, PMID 37957586, PMID 36583535, PMID 37156007, PMID 42770123, PMID 16885182, PMID 19455501, PMID 23359100, PMID 23924165, PMID 24554334, PMID 26677237, PMID 27258476, PMID 31053156, PMID 31655222, PMID 32727600, PMID 34331548, PMID 34496821, PMID 34751757, PMID 35585787, PMID 35854638, PMID 40403126, PMID 41360500, PMID 42805227
2014 (2), 2023 (2), 2017 (1), R01AR083628 (1)